This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
After a developmental day of shadowing a pharma sales rep, the fire was lite and she joined the sales team never looking back, ultimately landing her a role at ConnectiveRx in 2010. Laura is not shy about sharing her cancer experience. Laura has educated the new ConnectiveRx employees on the “real” patient journey.
In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. Currently, Jazz Pharmaceuticals’s nabiximols is the only cannabinoid approved for pain, receiving approval in Israel, in August 2010.
The landscape is highly competitive with new prescription medications launching worldwide each year. According to a McKinsey report , a startling 40% of biopharma products fail to meet their sales forecasts within the initial two years, prompting a critical reassessment of strategies for product launches.
In a press release, the company said a generic launch would damage sales in FY 2023 by $300,000. Ex-Novartis sales representative Steven Camburn filed a whistleblower case that claimed Novartis had paid doctors up to $3,500 to participate in educational speaker programs to increase the promotion and prescription of Gilenya.
Important elements within this expectation are the build up of strong contributions from Rotarix, Cervarix and Tykerb, while the outlook for GSK’s important asthma franchise becomes less clear beyond 2010. “Sales generated by new products are vital to the growth of the industry.”
On top of that, weve found that the best way to drive provider adoption is a mix of targeted digital marketing and in-person sales efforts. Our business has existed since around 2010. So many times, the prescription is not needed, and even when one is now written, it's just not going to work. or 48 continental states.
I have a big playlist of medical sales, medical information, news and innovation. While I was there, I met the hospice world, hospice sales and the ins and outs of hospice care. I remember back in my pharmaceutical sales rep days and I’m talking as far as 2009 or 2010. This is a whole new thing for you?
He was Executive VP and President of Merck’s Global Human Health Division from 2010 to 2019. Prior to becoming President of Global Human Health, he served as President of Merck’s global pharmaceutical business from 2007 to 2010. In this role, he was also a member of Merck’s executive committee.
I have to laugh when I hear that a pharma company is patient-centric because that’s become a slogan to make employees feel good about themselves while the costs of prescription drugs increase every year. Food and Drug Administration between 2010 and 2016 yet did taxpayers receive any discount? Centene Corp.,
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content